Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
NCT00108758
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
23
Enrollment
INDUSTRY
Sponsor class
Conditions
Congenital Bleeding Disorder
Haemophilia A With Inhibitors
Haemophilia B With Inhibitors
Interventions
DRUG:
activated recombinant human factor VII
Sponsor
Novo Nordisk A/S